 Alkermes plc Nasdaq: ALKS today announced the publication of results from the phase 3 ENLIGHTEN-2 clinical trial of ALKS 3831 olanzapinesamidorphan in the peer-reviewed publication, American Journal of Psychiatry. ENLIGHTEN-2 was a six-month study evaluating the weight gain profile of ALKS 3831 compared to olanzapine in 561 patients with stable schizophrenia. Positive topline data from the ENLIGHTEN-2 study were first reported in November 2018. 